1000 Spring Street
Silver Spring, MD 20910
United States
301 608 9292
https://www.unither.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 1 168
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D. | Founder, Chairman & CEO | 5,32M | 56,15M | 1955 |
Mr. Michael I. Benkowitz | President & COO | 2,83M | 7,83M | 1972 |
Mr. James C. Edgemond | CFO & Treasurer | 2,01M | 1,49M | 1968 |
Mr. Paul A. Mahon J.D. | Executive VP, General Counsel & Corporate Secretary | 2,31M | 13,2M | 1964 |
Mr. Dewey Steadman C.F.A. | Head of Investor Relations | S.O. | S.O. | S.O. |
Ms. Holly Hobson | Associate Vice President of Human Resources | S.O. | S.O. | S.O. |
Kevin T. Gray | Senior Vice President of Strategic Operations & Logistics | S.O. | S.O. | S.O. |
Mr. Patrick Poisson | Executive VP of Technical Operations | S.O. | S.O. | 1968 |
Dr. Leigh Peterson | Executive Vice President of Product Development & Xenotransplantation | S.O. | S.O. | S.O. |
Mr. Gil Golden | Senior VP & Chief Medical Officer | S.O. | S.O. | S.O. |
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
L’ISS Governance QualityScore de United Therapeutics Corporation en date du 29 avril 2024 est 2. Les scores principaux sont Audit : 1; Société : 5; Droits des actionnaires : 3; Compensation : 3.